Company profile for Dimerix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred therapies for areas of high unmet need. Our innovative technology identifies novel drug treatments by targeting specific receptor interactions. The lead candidate, DMX-200, is a promising therapy designed to transform the lives of patients with inflammatory kidney and lung diseases. Incorporated i...
Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred therapies for areas of high unmet need. Our innovative technology identifies novel drug treatments by targeting specific receptor interactions. The lead candidate, DMX-200, is a promising therapy designed to transform the lives of patients with inflammatory kidney and lung diseases. Incorporated in 2004, we are focused on commercializing our products for global markets and actively seek strategic collaborations for development and partnering.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
425 Smith Street Fitzroy VIC 3065
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/04/30/3072010/15991/en/Dimerix-and-Amicus-Therapeutics-Announce-Exclusive-License-Agreement-for-DMX-200-in-the-United-States.html

GLOBENEWSWIRE
30 Apr 2025

https://biomelbourne.org/dimerixs-dmx-200-posts-strong-results-in-kidney-disease-trial/

BIOMELBOURNE
29 Jul 2020

https://www.fool.com.au/2020/06/04/dimerix-share-price-doubles-after-being-included-in-global-covid-19-study/

Cathryn Goh FOOL
03 Jun 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty